Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
The myPKFiT software is intended for use by licensed healthcare professionals (HCPs) who are familiar with hemophilia care. The myPKFiT software can be used to generate ADVATE dosage amount and frequency recommendations for routine prophylaxis for an individual patient 16 years of age and older and body ...
Learn about AFSTYLA, recombinant FVIII therapy that delivers long-lasting bleed protection for patients with hemophilia A. Explore how to sign up your patients for a free 30-day trial.
Absorbable Hemostatic Particles
HCPs can find information about Bevyxxa, an oral anticoagulant, here.
Information for healthcare providers about ELOCTATE® [Antihemophilic factor (recombinant), Fc fusion protein].
Corifact, the first and only FDA-approved, natural FXIII concentrate indicated for routine prophylactic treatment of congenital Factor XIII (FXIII) deficiency.
The official HCP site for FEIBA. Please see Detailed Important Risk Information including BOXED WARNING and full Prescribing Information.
IXINITY® is a recombinant factor IX hemophilia B treatment option. Healthcare professionals, get IXINITY savings, dosage, and clinical information.
Official site from Bayer. Learn about Kogenate® FS, Antihemophilic Factor (Recombinant), including uses, safety and administration information.
Panzyga® is a human normal immunoglobulin solution stabilised with glycine.
CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy
Indications for COAGADEX. COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children (aged 12 years and above) with hereditary factor X deficiency for: On-demand treatment and control of bleeding episodes; Perioperative management of bleeding in patients with mild ...
Introducing CABLIVI: The first and only FDA-approved therapy for adult patients with aTTP
KOVALTRY®, Antihemophilic Factor (Recombinant), is the only unmodified, full-length rFVIII. Please see full Important Safety Information.
Learn about Nplate® (romiplostim) for adult chronic immune thrombocytopenia (ITP). Find prescribing info & medication guide for healthcare professionals.
HCP site for Rebinyn® Coagulation Factor IX (Recombinant), GlycoPEGylated, a treatment for hemophilia from Novo Nordisk. Read Important Safety ...
Learn more about OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], a recombinant porcine sequence factor.
Privigen® (Immune Globulin Intravenous [Human] 10% Liquid). See Boxed Warning.